Isavuconazole Therapeutic Drug Monitoring during Long-Term Treatment for Chronic Pulmonary Aspergillosis.


Journal

Antimicrobial agents and chemotherapy
ISSN: 1098-6596
Titre abrégé: Antimicrob Agents Chemother
Pays: United States
ID NLM: 0315061

Informations de publication

Date de publication:
16 12 2020
Historique:
received: 15 07 2020
accepted: 05 10 2020
pubmed: 21 10 2020
medline: 22 6 2021
entrez: 20 10 2020
Statut: epublish

Résumé

Isavuconazole is the newest triazole antifungal, and it displays a favorable pharmacokinetic and safety profile. Less is known about its long-term use in immunocompetent hosts. We performed a retrospective service evaluation of isavuconazole therapeutic drug monitoring in patients with chronic pulmonary aspergillosis. Adverse events (AEs) and dose adjustments made during routine clinical practice were recorded, and AEs were classified based on Common Terminology Criteria for Adverse Events v5.0. Forty-five patients (mean age, 64 years) had 285 isavuconazole blood drug levels measured (mean level, 4.1 mg/liter). A total of 117 measurements (41%) were performed on patients on a 100-mg daily dose instead of 200 mg, and all had blood levels of >1 mg/liter. Age (

Identifiants

pubmed: 33077653
pii: AAC.01511-20
doi: 10.1128/AAC.01511-20
pmc: PMC7927812
pii:
doi:

Substances chimiques

Antifungal Agents 0
Nitriles 0
Pyridines 0
Triazoles 0
isavuconazole 60UTO373KE

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2020 American Society for Microbiology.

Références

Mycoses. 2013 Sep;56(5):559-70
pubmed: 23496375
Eur Respir J. 2017 Feb 8;49(2):
pubmed: 28179437
Antimicrob Agents Chemother. 2018 Jun 26;62(7):
pubmed: 29735569
Mycoses. 2019 Mar;62(3):217-222
pubmed: 30570179
Drug Saf. 2009;32(1):55-68
pubmed: 19132805
Clin Infect Dis. 2016 Aug 15;63(4):e1-e60
pubmed: 27365388
Antimicrob Agents Chemother. 2019 May 24;63(6):
pubmed: 30962330
J Antimicrob Chemother. 2019 Mar 1;74(3):761-767
pubmed: 30476108
Int J Antimicrob Agents. 2018 Aug;52(2):258-264
pubmed: 29906567
Clin Infect Dis. 2010 Dec 15;51(12):1383-91
pubmed: 21054179
Eur Respir J. 2011 Apr;37(4):865-72
pubmed: 20595150
J Antimicrob Chemother. 2019 Aug 1;74(8):2341-2346
pubmed: 31119272
Eur Respir J. 2016 Jan;47(1):45-68
pubmed: 26699723
Lancet. 2016 Feb 20;387(10020):760-9
pubmed: 26684607
Eur J Clin Microbiol Infect Dis. 2012 Nov;31(11):3231-9
pubmed: 22782438
Antimicrob Agents Chemother. 2017 Nov 22;61(12):
pubmed: 28923872
Antimicrob Agents Chemother. 2016 Aug 22;60(9):5483-91
pubmed: 27381396

Auteurs

Chris Kosmidis (C)

National Aspergillosis Centre, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom chris.kosmidis@manchester.ac.uk.
Division of Infection, Immunity, and Respiratory Medicine, School of Biological Sciences, Faculty of Biology, Medicine, and Health, University of Manchester, Manchester, United Kingdom.

Akan Otu (A)

National Aspergillosis Centre, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom.
Department of Infection and Travel Medicine, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom.

Caroline B Moore (CB)

Mycology Reference Centre Manchester, ECMM Excellence Centre, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, United Kingdom.

Malcolm D Richardson (MD)

Division of Infection, Immunity, and Respiratory Medicine, School of Biological Sciences, Faculty of Biology, Medicine, and Health, University of Manchester, Manchester, United Kingdom.
Mycology Reference Centre Manchester, ECMM Excellence Centre, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, United Kingdom.

Riina Rautemaa-Richardson (R)

National Aspergillosis Centre, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom.
Division of Infection, Immunity, and Respiratory Medicine, School of Biological Sciences, Faculty of Biology, Medicine, and Health, University of Manchester, Manchester, United Kingdom.
Mycology Reference Centre Manchester, ECMM Excellence Centre, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH